Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by Barclays PLC

Barclays PLC grew its stake in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOSFree Report) by 280.9% in the 3rd quarter, HoldingsChannel reports. The firm owned 167,718 shares of the company’s stock after acquiring an additional 123,683 shares during the quarter. Barclays PLC’s holdings in Atossa Therapeutics were worth $255,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of ATOS. Geode Capital Management LLC lifted its stake in Atossa Therapeutics by 1.6% during the third quarter. Geode Capital Management LLC now owns 2,814,446 shares of the company’s stock valued at $4,278,000 after buying an additional 44,762 shares in the last quarter. XTX Topco Ltd raised its holdings in shares of Atossa Therapeutics by 101.2% during the third quarter. XTX Topco Ltd now owns 49,616 shares of the company’s stock valued at $75,000 after acquiring an additional 24,951 shares during the period. State Street Corp lifted its position in shares of Atossa Therapeutics by 4.2% in the 3rd quarter. State Street Corp now owns 1,732,221 shares of the company’s stock valued at $2,633,000 after acquiring an additional 69,180 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in Atossa Therapeutics in the 3rd quarter worth approximately $75,000. Finally, Intech Investment Management LLC purchased a new position in Atossa Therapeutics during the 3rd quarter worth approximately $29,000. Institutional investors and hedge funds own 12.74% of the company’s stock.

Atossa Therapeutics Trading Down 2.5 %

NASDAQ ATOS opened at $0.83 on Tuesday. Atossa Therapeutics, Inc. has a 1-year low of $0.77 and a 1-year high of $2.31. The firm’s fifty day simple moving average is $1.10 and its 200-day simple moving average is $1.28. The company has a market capitalization of $103.87 million, a PE ratio of -3.75 and a beta of 1.26.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on ATOS shares. HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Atossa Therapeutics in a report on Thursday, December 12th. Ascendiant Capital Markets raised their price objective on Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Finally, StockNews.com cut Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, November 18th.

Check Out Our Latest Stock Analysis on ATOS

About Atossa Therapeutics

(Free Report)

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

Read More

Want to see what other hedge funds are holding ATOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atossa Therapeutics, Inc. (NASDAQ:ATOSFree Report).

Institutional Ownership by Quarter for Atossa Therapeutics (NASDAQ:ATOS)

Receive News & Ratings for Atossa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.